Rexahn Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of first-in-class and market-leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. The company currently has three drug candidates in Phase II clinical trials: Archexin, Serdaxin and Zoraxel. Rexahn Pharmaceuticals additionally has a robust pipeline of preclinical compounds for treating multiple cancers and CNS disorders. For more information, visit the company’s Web site at www.rexahn.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: